CRESCENT BIOPHARMA, INC. Restructuring and Related Cost, Number of Positions Eliminated
CRESCENT BIOPHARMA, INC. (CBIO) reported Restructuring and Related Cost, Number of Positions Eliminated of 26 employee for the 1-month period ending 2024-07-31, per its 10-K filed 2025-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2025-02-13
- 2024-07-31: Restructuring and Related Cost, Number of Positions Eliminated 1 month 26.00 employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|
| 2024-07-31 | 26.00 employee 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |